Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

40 trials with published results (35%)

Research Maturity

77 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.3%

6 terminated out of 114 trials

Success Rate

92.8%

+6.3% vs benchmark

Late-Stage Pipeline

38%

43 trials in Phase 3/4

Results Transparency

52%

40 of 77 completed with results

Key Signals

40 with results93% success

Data Visualizations

Phase Distribution

106Total
Not Applicable (27)
P 1 (9)
P 2 (27)
P 3 (36)
P 4 (7)

Trial Status

Completed77
Unknown21
Terminated6
Recruiting5
Withdrawn3
Not Yet Recruiting2

Trial Success Rate

92.8%

Benchmark: 86.5%

Based on 77 completed trials

Clinical Trials (114)

Showing 20 of 20 trials
NCT06120764Not ApplicableRecruitingPrimary

Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting

NCT05838638Not ApplicableRecruiting

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT07482891Phase 4RecruitingPrimary

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC

NCT07322393Not ApplicableNot Yet RecruitingPrimary

Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients

NCT07540169Not ApplicableRecruiting

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

NCT06331520Phase 3CompletedPrimary

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

NCT03354741Not ApplicableCompleted

Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children

NCT02106494Phase 3CompletedPrimary

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT04817189Phase 4CompletedPrimary

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

NCT07081256Phase 3CompletedPrimary

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

NCT05590923Phase 4TerminatedPrimary

Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

NCT05143554Not ApplicableTerminatedPrimary

Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting

NCT03232541Not ApplicableCompleted

The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting

NCT05805800Phase 3CompletedPrimary

Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

NCT05319860Phase 2CompletedPrimary

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

NCT03984214Phase 3Completed

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

NCT04054193Phase 4CompletedPrimary

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT05885126Not ApplicableCompletedPrimary

The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients

NCT05242874Phase 3CompletedPrimary

Anti-emetic Prophylaxis With or Without Dexamethasone

NCT00273468Phase 3CompletedPrimary

To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)

Scroll to load more

Research Network

Activity Timeline